4851 Tamiami Trail N
Suite 200
Naples, FL 34103
United States
239-302-1707
https://www.enveric.com
Secteur(s): Healthcare
Secteur d’activité: Biotechnology
Employés à temps plein: 7
Nom | Titre | Payer | Exercé | Année de naissance |
---|---|---|---|---|
Dr. Joseph Edward Tucker Ph.D. | CEO & Director | 450,79k | S.O. | 1969 |
Mr. Kevin M. Coveney CPA | Chief Financial Officer | 385,62k | S.O. | 1964 |
Dr. Peter J. Facchini Ph.D. | Chief Innovation Officer | 233,27k | S.O. | 1964 |
Enveric Biosciences, Inc., a biotechnology company, engages in the development of small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders. Its lead product candidates are EB-002, an active metabolite of psilocybin, which is in preclinical development stage for the treatment of anxiety disorders; and EB-003 that is in preclinical development stage for the treatment mental health. The company also focuses on the development of cannabinoid conjugate molecules for the treatment of pain and cancer. Enveric Biosciences, Inc. is headquartered in Naples, Florida.
L’ISS Governance QualityScore de Enveric Biosciences, Inc. en date du S.O. est S.O.. Les scores principaux sont Audit : S.O.; Société : S.O.; Droits des actionnaires : S.O.; Compensation : S.O..